

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C12N 5/00	A1	(11) International Publication Number: WO 92/18615 (43) International Publication Date: 29 October 1992 (29.10.92)
(21) International Application Number: PCT/US92/02895 (22) International Filing Date: 9 April 1992 (09.04.92) (30) Priority data: 682,344 9 April 1991 (09.04.91) US (60) Parent Application or Grant (63) Related by Continuation US 682,344 (CIP) Filed on 9 April 1991 (09.04.91) (71) Applicant (for all designated States except US): INDIANA UNIVERSITY FOUNDATION [US/US]; Showalter House, P.O. Box 500, Bloomington, IN 47402 (US).		(72) Inventors; and (75) Inventors/Applicants (for US only) : HOFFMAN, Ronald [US/US]; 5305 North Pennsylvania Street, Indianapolis, IN 46220 (US). BRANDT, John [US/US]; 6312 Doug- las Road, Indianapolis, IN 46220 (US). (74) Agents: HENRY, Thomas, Q. et al.; Woodard, Emhardt, Naughton, Moriarty & McNett, Bank One Center/Tow- er, Suite 3700, 111 Monument Circle, Indianapolis, IN 46204 (US). (81) Designated States: AT (European patent), BE (European patent), CA, CH (European patent), DE (European pa- tent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (Euro- pean patent), IT (European patent), JP, LU (European patent), MC (European patent), NL (European patent), SE (European patent), US. Published <i>With international search report.</i> <i>With amended claims.</i>
(54) Title: SYSTEM AND PROCESS FOR SUPPORTING HEMATOPOIETIC CELLS (57) Abstract A process for supporting hematopoietic progenitor cells in a culture medium which contains at least one cytokine effective for supporting the cells, and preferably, is essentially free of stromal cells.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FI	Finland	ML	Mali
AU	Australia	FR	France	MN	Mongolia
BB	Barbados	GA	Gabon	MR	Mauritania
BE	Belgium	GB	United Kingdom	MW	Malawi
BF	Burkina Faso	GN	Guinea	NL	Netherlands
BG	Bulgaria	GR	Greece	NO	Norway
BJ	Benin	HU	Hungary	PL	Poland
BR	Brazil	IE	Ireland	RO	Romania
CA	Canada	IT	Italy	RU	Russian Federation
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark	MG	Madagascar		
ES	Spain				

**SYSTEM AND PROCESS FOR SUPPORTING
HEMATOPOIETIC CELLS**

This application is a continuation-in-part of U.S. Serial No. 07/682,344, filed April 9, 1991.

This invention relates to a system and process for supporting human stem cells and more particularly the present invention relates to supporting hematopoietic stem cells for use in bone marrow transplant patients.

Mammalian hematopoiesis has been studied in vitro through the use of various long-term marrow culture systems (3, 10-12). Dexter and co-workers (3) described a murine system from which CFU-S and CFU-GM could be assayed for several months, with erythroid and megakaryocytic precursors appearing for a more limited time. Maintenance of these cultures was dependent on the formation of an adherent stromal cell layer composed of endothelial cells, adipocytes, reticular cells, and macrophages. These methods were soon adapted for the study of human bone marrow. Human long-term culture systems were reported to generate assayable hematopoietic progenitor cells for 8 or 9 weeks (10, 11) and, later, for up to 20 weeks (12, 13). Such cultures are again relying on the pre-establishment of a stromal cell layer which is frequently reinoculated with a large, heterogeneous population of marrow cells. Hematopoietic stem cells have been shown to home and adhere to this adherent cell multilayer before generating and releasing more committed progenitor cells (1, 14, 15). Stromal cells are thought to provide not only a physical matrix on which stem cells reside, but also to produce membrane-contact signals and/or hematopoietic growth factors necessary for stem cell

-2-

proliferation and differentiation (4, 5, 16, 17). This heterogeneous mixture of cells comprising the adherent cell layer presents an inherently complex system from which the isolation of discrete variables affecting stem cell growth has proven difficult.

Recently, a study was conducted by McNiece and Langley which examined the stimulatory effect of recombinant human stem cell factor (MGF) on human bone marrow cells alone and in combination with recombinant human colony stimulating factors, GM-CSF, IL-3 and erythropoietin. The results showed that MGF stimulation of low density non-adherent, antibody depleted CD34⁺ cells suggests that MGF directly stimulates progenitor cells capable of myeloid and erythroid differentiation (18).

In accordance with an aspect of the present invention there is provided a process for supporting mammalian bone marrow cells wherein such cells are maintained in a culture medium essentially free of stromal cells and which includes at least one cytokine effective for supporting such cells.

Preferred embodiments of this aspect of the present invention provide a process for supporting bone marrow cells which are hematopoietic stem cells, a process for supporting bone marrow cells which are hematopoietic progenitor cells and a process for supporting bone marrow cells which are CD34⁺DR⁻CD15⁻ cells.

In addition, this invention provides that at least one cytokine be selected from the following cytokines: Interleukin (IL)-1, IL-3, IL-6, granulocyte/macrophage-colony stimulating factor (GM-CSF), human or murine stem cell factor, sometimes referred to as human or murine mast cell growth factor (MGF) and a fusion protein of GM-CSF/IL-3 (FP). Further, this invention provides particularly preferred embodiments wherein the cytokine MGF is included as the sole cytokine or in combination with at least one other cytokine.

-3-

In accordance with another aspect of the present invention there is provided a process for supporting mammalian bone marrow cells wherein such cells are maintained in a culture medium containing a combination of cytokines effective for supporting such cells. Preferably, the bone marrow will be supported in a culture medium which is essentially free of stromal cells.

Another aspect of the present invention provides for a process of supporting mammalian bone marrow cells wherein such cells are maintained in a culture medium which is essentially free of serum and of stromal cells. This system allows for preferred expansion of progenitor cell numbers and enables the identification of which cytokines specifically affect progenitor cell expansion.

Another aspect of the present invention provides for a process of supporting mammalian bone marrow cells wherein such cells are maintained in a culture system which is essentially a serum-free long-term suspension human bone marrow. This system allows for preferred expansion of human progenitor cell numbers and enables the identification of which cytokines specifically affect human progenitor cell expansion. Preferably, the medium is essentially free of stromal cells.

Additional preferred embodiments of this invention provide a process for supporting bone marrow cells which are hematopoietic stem cells, a process for supporting bone marrow cells which are hematopoietic progenitor cells and a process for supporting bone marrow cells which are CD34⁺DR⁻CD15⁻ cells.

Preferably, the culture medium will contain at least one of the following cytokine combinations: IL-1/IL-3; IL-3/IL-6; IL-3/KGF; IL-3/GM-CSF; MGF/FP. Applicant has found that such combinations provide for an improved rapid expansion of the cells population.

The term "supporting" with respect to stem cells and

SUBSTITUTE SHEET

-4-

other progenitor cells means maintaining and/or expanding and/or promoting some differentiation of such cells.

The following are representative examples of cytokines which may be employed in the present invention: IL-1 in an amount effective to support the cells. Generally, such amount is at least 20 pg/ml and need not exceed 1 ng/ml, preferably 1 ng/ml; IL-6 in an amount effective to support the cells. Generally, such amount is at least 20pg/ml and need not exceed 1 ng/ml, preferably 1 ng/ml; IL-6 in an amount effective to support the cells. Generally, such amount is at least 1 ng/ml and need not exceed 50 ng/ml preferably 10 ng/ml; IL-3 in an amount effective to support the cells. Generally, such amount is at least 500 pg/ml and need not exceed 2 ng/ml preferably 500 pg/ml; GM-CSF in an amount effective to support the cells. Generally, such amount is at least 100 pg/ml and need not exceed 1 ng/ml, preferably 200 pg/ml; MGF in an amount effective to support the cells. Generally, such amount is at least 10 ng/ml and need not exceed 50 ng/ml, preferably 50 ng/ml; and FP in an amount effective to support the cells. Generally, such amount is at least 1 ng/ml and need not exceed 10 ng/ml, preferably 10 ng/ml. Such cytokines may be employed alone or in combination with each other.

The use of a cytokine in the absence of stromal cells is particularly suitable for expanding the mammalian bone marrow stem cells and in particular progenitor cells. The cells which are supported in accordance with the present invention are preferably of human origin.

In accordance with a preferred aspect of the present invention, a cell population which is supported in accordance with the present invention is that which is positive for CD34 antigen and is negative for HLA-DR and is also negative for CD15.

Specifically, this aspect of the present invention provides for cell population of $CD34^{+}DR^{-}CD15^{-}$

-5-

supported in accordance with the process described above, where the population has doubled in a period of time which does not exceed 15 days. Preferably, the population has doubled in 7 to 15 days.

5 In accordance with another aspect, the present invention provides for a cell population of bone marrow cells supported in accordance with the process described herein, where the population has doubled in a period of time which does not exceed 15 days. Preferably, the population has doubled in 7
10 to 15 days.

In accordance with another aspect, the present invention provides for a cell population of hematopoietic stem cells supported in accordance with the process described herein, wherein the population has doubled in a period of time which
15 does not exceed 15 days. Preferably, the population has doubled in 7 to 15 days.

In accordance with another aspect, the present invention provides for a cell population of hematopoietic progenitor cells supported in accordance with the process described
20 herein, where the population has doubled in a period of time which does not exceed 15 days. Preferably, the population has doubled in 7 to 15 days.

Another aspect of the present invention provides for a composition comprised of an expanded bone marrow cell culture
25 which is essentially free of stromal cells, the culture also contains at least one cytokine and the culture's cell population has doubled in a time not exceeding 15 days. Preferably, the cell population will have doubled in at least 7 and not exceeding 15 days.

30 Human long-term bone marrow cultures (LTBMC) have been though to require the formation of an adherent stromal cell layer for sustained in vitro hematopoiesis. The CD34⁺DR⁻CD15⁻ population of human marrow cells are capable of multilineage differentiation, self-renewal, and of
35 initiating LTBMC in the absence of stromal cells for up to 12

-6-

weeks when continually supplied with cytokines. Preferably the cytokine supplied is interleukin-3 (IL-3). The effects of stromal cells on CD34⁺DR⁻CD15⁻ cells in the presence and absence of IL-3 in LTBMCM have been observed. Suspension
5 cultures of CD34⁺DR⁻CD15⁻ cells in the absence of stroma were characterized by sustained hematopoiesis for 10-12 weeks as demonstrated by a high degree of cellular proliferation and multilineage progenitor cell expansion when supplied with IL-3. No adherent layer formed in these
10 cultures, and IL-3 was necessary for their survival beyond one week. Such stroma-free cultures produced 500 to more than 900 assayable CFU-GM over a 12-week period, while BFU-E were generated for 1-3 weeks. By contrast, 4-week-old stromal cultures recharged with autologous
15 CD34⁺DR⁻CD15⁻ cells both in the presence and absence of exogenous IL-3 generated far fewer (100-500) assayable colony-forming cells for only six weeks, and production of nonadherent cells was greatly reduced over the 12-week observation period. Stromal cultures supplemented with IL-3
20 but not re-seeded with CD34⁺DR⁻CD15⁻ cells behaved similarly to those to which sorted cells were added. These data suggest that marrow stromal cells modulate the effects of cytokines on hematopoietic stem cell development and proliferation and elaborate signals that both promote and
25 dampen in vitro hematopoieses.

An additional aspect of the present invention provides for a composition comprised of an expanded bone marrow cell culture which contains a combination of cytokines and the cultures cell population has doubled in a time not to exceed
30 15 days. Preferably the cell population has doubled in at least 7 and not exceeding 15 days. It is also preferable, that the cell culture be essentially free of stromal cells.

As previously indicated, the present invention is particularly applicable to bone marrow cells that are
35 positive for CD34 antigen but which do not express HLA-DR,

-7-

CD15 antigens in that it is believed that such cell population is believed to be closely associated with human hematopoietic stem cells, but it is to be understood that the present invention is not limited to supporting such a cell population.

The cells supported in accordance with the present invention may be used in a variety of ways. For example, such cells may be employed as part of a bone marrow transfer procedure.

Expanded hematopoietic stem cell populations can be used as grafts for marrow transplantation to treat malignancies, bone marrow failure states and congenital metabolic, immunologic and hematological disorders. Marrow samples will be taken from patients with cancer and $CD34^{+}DR^{-}CD15^{-}$ cells isolated by means of density centrifugation, counterflow centrifugal elutriation, monoclonal antibody labeling and fluorescence activated cell sorting. The stem cells in this cell population will then be expanded in vitro and will serve as a graft for autologous marrow transplantation. The graft will be infused after the patient has received curative chemo-radiotherapy.

Expanded stem cell populations can also be utilized for in utero transplantation during the first trimester of pregnancy. Fetuses with metabolic and hematologic disorders will be diagnosed prenatally. Marrow will be obtained from normal individuals and $CD34^{+}DR^{-}CD15^{-}$ cells will be obtained by the methods described previously and expanded in vitro. They will then be administered to the fetus by in utero injection. A chimera will be formed which will lead to partial but clinically significant alleviation of the clinical abnormality.

The invention will be further described with respect to the following examples; however, the scope of the invention is not to be limited thereby:

SUBSTITUTE SHEET

-8-

EXAMPLE 1

A. Materials and Procedures

Prior to performing any procedures, informed consent was obtained from all volunteers according to the guidelines of the Human Investigation Committee of the Indiana University School of Medicine.

Cell separation techniques. Bone marrow aspirates were collected from the posterior iliac crests of normal volunteers. Low-density mononuclear bone marrow (LDBM) cells were obtained by density centrifugation of the heparinized marrow over Ficoll-Paque (Pharmacia Fine Chemicals, Piscataway, NJ) at 500 g for 25 min. LDBM cells were suspended in PBS-EDTA (PBS, pH 7.4, containing 5% FBS, 0.01% EDTA wt/vol, and 1.0 g/liter D-glucose) and injected into an elutriator system at 10°C at a rotor speed of 1,950 rpm using a JA-17 rotor and standard separation chamber (Beckman Instruments, Inc., Palo Alto, CA). A fraction of the LDBM eluted at a flow rate of 12-14 ml/min (FR 12-14), enriched for hematopoietic precursors, was collected as previously described (2).

Long-term marrow cultures free of stromal cells. Plastic 35-mm tissue culture dishes were seeded with 2×10^6 LDBM cells in 1 ml of Iscove's with 10% FBS and 2×10^{-5} M methylprednisolone. Cultures were incubated at 37°C in 100% humidified atmosphere containing 5% CO₂ in air and fed weekly by total replacement of media. Stromal cells were confluent by 4-6 wk. The stromal cultures were then irradiated with 1,500 rad, the media were replaced, and the cultures were inoculated with 5×10^3 sorted bone marrow cells from autologous donors. The media in these cultures were removed at 7-10 d intervals and replaced with fresh media. Suspended, nonadherent cells were then counted and

-9-

assayed for progenitors.

Long-term suspension cultures. Plastic 35-mm tissue culture dishes containing 1 ml of Iscove's with 10% FBS were inoculated with stromal cell free long term marrow cells containing 5×10^3 cells obtained by sorting and incubated at 37°C in 100% humidified atmosphere containing 5% CO₂ in air. At this time, and every 48 h thereafter, cultures received nothing (1% BSA/PBS), 2.5 U/ml IL-1a, 50 U/ml IL-3, 75 U/ml IL-6, 12.5 U/ml GM-CSF, or combinations of the above. At 7d intervals, cultures were demi-depopulated by removal of one-half the culture volume which was replaced with fresh media. Cells in the harvested media were counted, transferred to slides for staining and morphological examination, and assayed for various progenitor cells.

Hematopoietic growth factors. All cytokines were obtained from the Genzyme Corp., Boston, MA. Recombinant IL-1a and IL-3 each had a specific activity of 10^8 CFU/mg protein, while that of IL-6 was 10^7 and granulocyte/macrophage colony-stimulating factor (GM-CSF) 5×10^7 CFU/mg protein.

Two- and three-color cell sorting. FR 12-14 cells were incubated with mouse monoclonal anti-HPCA-1 (CD34) of the IgG₁ subclass (Becton Dickinson Immunocytometry Systems, San Jose, CA), washed, and stained with Texas red-conjugated, subclass-specific goat anti-mouse IgG₁ (Southern Biotechnology Associates, Inc., Birmingham, AL). Cells were next incubated with mouse serum to block any unbound active sites on the second-step antibody. Cells were finally stained with phycoerythrin-conjugated mouse anti-HLA-DR either alone or in combination with FITC-conjugated CD33 (My9, Coulter Immunology, Hialeah, FL), CD15 (Leu-M1), or CD71 (transferring receptor) (Becton Dickinson Immunocytometry Systems). CD15 is present on cells of the granulocytic and monocytic lineages, and an anti-CD15 monoclonal antibody was employed in the hope of eliminating

-10-

these cellular components from the cell populations (6).
CD71 is present on actively proliferating cells and an
anti-CD71 antibody was utilized to separate actively
proliferating cells from more quiescent marrow elements (7).
Controls consisted of the corresponding isotype-matched,
nonspecific myeloma proteins used in parallel with staining
monoclonal antibodies. Cells were stained at a concentration
of 2×10^7 /ml and washed after each step in 1% BSA in PBS.
A temperature of 4°C was maintained throughout the procedure.

Immediately after staining, cells were sorted on a
Coulter Epics 753 dual-laser flow cytometry system (Coulter
Electronics, Inc., Hialeah, FL). Texas red was excited by
590 nm light emitted from a rhodamine 6G dye laser. FITC and
phycoerythrin were excited using the 488 nm wavelength from a
dedicated 6-W argon laser. Sorting windows were first
established for forward angle light scatter (FALS) and Texas
red fluorescence. Positivity for each fluorochrome was
defined as fluorescence > 99% of that of the controls.
Cells were next gated on the presence or absence of
detectable HLA-DR-phycoerythrin and CD33-FITC, CD15-FITC, or
CD71-FITC.

Hematopoietic progenitor cells assays. Cells were
suspended at various concentrations in 35-mm plastic tissue
culture dishes (Costar Data Packaging, Cambridge, MA)
containing 1ml of 30% FBS, 5×10^{-5} M 2-mercaptoethanol, 1
U human purified erythropoietin (50 U/mg protein, Toyobo Co.
Ltd., Osaka, Japan), 50 U GM-CSF, and 1.1% methylcellulose in
Iscoe's modified Dulbecco's medium. The cultures were
incubated at 37°C in a 100% humidified atmosphere containing
5% CO_2 in air. After 14 d, erythropoietic bursts (BFU-E),
granulocyte-macrophage (CFU-GM), and mixed lineage (CFU-GEMM)
colonies were scored in situ on an inverted microscope using
standard criteria for their identification (2).

High proliferative potential colony-forming cell
(HPP-CFC)-derived colonies were enumerated after 28 d in

-11-

culture according to the recently published criteria of McNiece and co-workers (8). The human HPP-CFC derived colony is a late-appearing, very large (0.5 mm or more in diameter) colony composed primarily of granulocytes with a lesser
5 number of monocytes; cell numbers frequently exceed 50,000.

Cells removed from suspension cultures were assayed for CFU-megakaryocyte (CFU-MK) colonies using the serum-depleted method described in detail by Bruno et al. (9) 5×10^3 cells per point were suspended in a 1-ml serum-substituted
10 fibrin clot with 100 U of IL-3 in 35-mm culture dishes and incubated at 37°C in a 100% humidified atmosphere containing 5% CO₂ in air. At 18-24 d, cultures were fixed in situ and stained using rabbit anti-human platelet glycoprotein antisera, and fluorescein-conjugated goat F(ab')₂-specific
15 anti-rabbit IgG (Tago, Inc., Burlingame, CA) and megakaryocyte colonies were enumerated on a Zeiss fluorescence microscope (Carl Zeiss, Inc., New York, NY). A positive colony was defined as a cluster of three or more fluorescent cells.

20 B. Experiments

A liquid culture system supplemented with repeated 48-hourly cytokine additions was utilized to study cell populations. Total cell production by both CD34⁺DR⁻CD15⁻ and CD34⁺DR⁻CD71⁻ cells is shown in
25 Tables I and II while assayable CFU-GM in these cultures over time are recorded in Tables III and IV. In the absence of exogenous cytokines, total cell numbers declined over a 2-wk period and assayable CFU-GM persisted for only 1 or 2 wk. The repeated addition of IL-1a did not significantly enhance
30 total cell production or generation of CFU-GM by either CD34⁺DR⁻CD15⁻ or CD34⁺DR⁻CD71⁻ cells. IL-6 did not alter total cell numbers or numbers of assayable CFU-GM in cultures initiated with CD34⁺DR⁻CD71⁻ cells. By

SUBSTITUTE SHEET

-12-

contrast, IL-6 increased total cell numbers over seven fold by week 3 by CD34⁺DR⁻CD15⁻ initiated cultures but did not appreciably extend the interval over which CFU-GM were detected. In both sets of experiments, GM-CSF promoted increased total cell production for 6 wk, by which time cell numbers represented 20-80 times the number present in the initial seeding populations. Assayable CFU-GM persisted for 3-4 wk and cumulatively surpassed those assayable in the initial populations. The single most effective cytokine in terms of promoting cellular expansion, increasing the number of CFU-GM, and lengthening the duration of time over which CFU-GM were assayable was IL-3. Both CD34⁺DR⁻CD15⁻ and CD34⁺DR⁻CD71⁻ cells experienced 200-fold increases in cell numbers by day 28, and, after 1 or 2 wk in culture, contained equal or slightly greater numbers of CFU-GM than present in the initial inoculi. Assayable progenitors were produced for 4-5 wk in the system when maintained with IL-3, and viable cell counts remained high at 8 wk. IL-1a or IL-6 prolonged and enhanced these effects when added in combination with IL-3. CFU-GM were assayable after 8 wk in suspension culture after continued treatment with these two cytokine combinations. No adherent cell layer was established in any of the suspension cultures over the 8 wk period of observation.

In a separate experiment, CD34⁺DR⁻CD71⁻ cells were grown in this suspension culture system in the presence of a combination of both IL-3 and IL-6 and assayed for CFU-MK from days 7 through 28 of culture. CFU-MK were detected over this 28 d period (Table V). Utilizing this IL-3/IL-6 cytokine combination, the ability of CD34⁺DR⁻CD15⁺ and CD34⁺DR⁻CD71⁺ cells to sustain long-term hematopoiesis was compared to that of the CD34⁺DR⁻CD15⁻ and CD34⁺DR⁻CD71⁻ fractions (Table VI). Both the CD15-positive and CD71-positive calls failed to generate CFU-GM after 2 wk, and the CD71-positive population, which

-13-

initially included the overwhelming majority of BFU-E, failed to produce assayable BFU-E after only 7 d in culture.

Morphological analysis of the cells in these suspension cultures during the period of observation revealed changes in the cellular composition of the populations following the addition of various cytokines (Tables VII and VIII). IL-1 α -and IL-6-containing cultures behaved very similarly to the control samples. Cultures to which no cytokines were added were composed of 90-100% blasts after 1 wk; the CD34⁺DR⁻CD15⁻ cells did not survive 2 wk in the absence of cytokine whereas the CD34⁺DR⁻CD71⁻ initiated cultures were composed of 40% blasts and 60% monocytes by week 2. Cultures receiving IL-1 α had a similar cellular composition. IL-6 facilitated some differentiation to the granulocytic series by both cell populations; the CD34⁺DR⁻CD15⁻ cells produced a significant number of mature granulocytic elements by week 2. GM-CSF, as well as IL-3, reduced the percentage of blasts in these suspension cultures appreciably by day 7. GM-CSF-containing cultures of CD34⁺DR⁻CD15⁻ cells consisted primarily of metamyelocytes through 4 wk, with a shift to monocytes occurring by week 6.

IL-3 was unique in that, at 3 wk, suspension cultures initiated by either CD34⁺DR⁻CD15⁻ or CD34⁺DR⁻CD71⁻ cells were composed of 48% basophils in the presence of this growth factor (Tables VII and VIII). Addition of IL-1 α or IL-6 did not alter this trend, all IL-3-containing cultures being composed of about 50% basophils by 3 wk and retaining significant numbers of basophils throughout the duration of culture.

The cellular composition of hematopoietic colonies assayed from aliquots of the suspension cultures was comparable to those assayed from the original sorted populations with a few notable exceptions. Blast cell colonies, as well as HPP-CFC-derived colonies, were routinely

SUBSTITUTE SHEET

-14-

obtained by directly assaying $CD34^+DR^-CD15^-$ or $CD34^+DR^-CD71^-$ cells while these colony types were not observed in subsequent clonal assays of cellular aliquots obtained from the long-term liquid cultures. Distribution of GM colony subtypes, however, remained fairly consistent with roughly 40% being granulocyte/macrophage, 40% monocyte/macrophage, and 20% basophil or eosinophil colonies in either assays initiated with sorted cells of those initiated on days 7 through 42 of liquid culture. These CFU-GM-derived colonies ranged in size from 100 to 2,000 cells with the average colony containing between 200 to 400 cells. After 8 wk of suspension culture, monocyte/macrophage colonies were the predominant colony type observed in the clonal assays.

Table I. Total Cell production of $CD34^+$, DR^- , $CD15^-$ Cells after Addition of Various Cytokines

		Day							
	Cytokine	0	7	14	21	28	35	42	56
		viable cell count x 10 ³							
20	None	5	1	4	0	0	0	0	0
	IL-1	5	2	2	0	0	0	0	0
	IL-3 ⁺	5	53	140	591	1,085	533	678	781
	IL-6§	5	3	4	36	26	16	0	0
	GM-CSF°	5	8	14	44	169	213	118	0
25	IL-1a/IL-3	5	32	167	556	1,360	1,387	758	1,069
	IL-6/IL-3	5	47	171	471	854	1,440	1,200	1,216

-15-

Total cells = cells/ml culture $(1/2)^n$, where n = number of previous demi-depopulations.

*2.5 U/ml recombinant human IL-1a were added every 48 h;
specific activity 10^8 CFU/mg protein.

5 + 50 U/ml recombinant human IL-3 were added every 48 h;
specific activity 10^8 CFU/mg protein.

§75 U/ml recombinant human IL-6 were added every 48 h; specific activity 10^7 CFU/mg protein.

10 ° 12.5 U/ml recombinant human GM-CSF were added every 48 h;
specific activity 5×10^7 CFU/mg protein.

Table II. Total Cell Production of CD34⁺, DR⁻. CD71⁻
Cells after Addition of Various Cytokines

	Cytokine	Day							
		0	7	14	21	28	35	42	56
15		viable cell count $\times 10^3$							
	None	5	1	2	0	0	0	0	0
	IL-1 *	5	3	0	0	0	0	0	0
	IL-3 ⁺	5	40	226	964	746	1,190	1,120	851
	IL-6§	5	1	2	0	0	0	0	0
20	GM-CSF°	5	3	34	44	45	445	438	0
	IL-1a/IL-3	5	23	202	684	1,112	835	800	1,067

Total cells = cells/ml culture $(1/2)^n$, where n = number of previous demi-depopulations.

25 *2.5 U/ml recombinant human IL-1a were added every 48 h;
specific activity 10^8 CFU/mg protein.

+ 50 U/ml recombinant human IL-3 were added every 48h; specific activity 10^8 CFU/mg protein.

§75 U/ml recombinant human IL-6 were added every 48 h; specific activity 10^7 CFU/mg protein.

-16-

° 12.5 U/ml recombinant human GM-CSF were added every 48 h;
specific activity 5×10^7 CFU/mg protein.

Table III. Total CFU-GM Production by $CD34^+$, DR^- , $CD15^-$
Cells after Addition of Various Cytokines

5	Cytokine	Week						
		1	2	3	4	5	6	7
		CFU-GM/ml culture						
	None	40	0	0	0	0	0	0
	IL-1 *	22	14	0	0	0	0	0
10	IL-3 ⁺	432	696	591	325	0	0	0
	IL-6§	42	242	96	0	0	0	0
	GM-CSF°	273	200	219	0	0	0	0
	IL-1a/IL-3	254	397	444	408	139	152	64
	IL-6/IL-3	98	342	236	768	864	1,080	384

15 Total CFU-GM = CFU-GM/ml culture $(1.2)^n$, where n = number of
previous demi-populations.
Cells were seeded at 5×10^3 /ml. CFU-GM in initial (day 0)
population = $555/5 \times 10^3$ cells. Colonies grown in
bethylcellulose containing 50 U/ml GM-CSF and enumerated after
20 14 d.

*2.5 U/ml recombinant human IL-1α were added every 48 h;
specific activity 10^8 CFU/mg protein.

+ 50 U/ml recombinant human IL-3 were added every 48 h; specific
activity 10^8 CFU/mg protein.

25 §75 U/ml recombinant human IL-6 were added every 48 h; specific
activity 10^7 CFU/mg protein.

° 12.5 U/ml recombinant human GM-CSF were added every 48 h;
specific activity 5×10^7 CFU/mg protein.

-17-

Table IV. Total CFU-GM Production by CD34⁺, DR⁻, CD71⁻ Cells after Addition of Various Cytokines

		Week						
	Cytokine	1	2	3	4	5	6	8
5		CFU-GM/ml culture						
	None	15	4	0	0	0	0	0
	IL-1 *	20	0	0	0	0	0	0
	IL-3 ⁺	664	272	96	448	119	0	0
	IL-6§	51	14	0	0	0	0	0
10	GM-CSF°	402	360	135	28	0	0	0
	IL-1 /IL-3	347	324	342	334	167	240	214

Total CFU-GM = CFU-GM/ml culture $(1/2)^n$, where n = number of previous demi-populations.

Cells were seeded at 5×10^3 /ml. CFU-GM in initial (day 0) population = $690/5 \times 10^3$ cells. Colonies grown in methylcellulose containing 50 U/ml GM-CSF and enumerated after 14 d.

*2.5 U/ml recombinant human IL-1a were added every 48 h; specific activity 10^8 CFU/mg protein.

+ 50 U/ml recombinant human IL-3 were added every 48 h; specific activity 10^8 CFU/mg protein.

§75 U/ml recombinant human IL-6 were added every 48 h; specific activity 10^7 CFU/mg protein.

° 12.5 U/ml recombinant human GM-CSF were added every 48 h; specific activity 5×10^7 CFU/mg protein.

Table V. Assayable CFU-MK in Long-Term Suspension Cultures of CD34⁺ DR⁻CD71⁻ Cells Receiving a Combination of IL-3 and IL-6

	Days in culture* CFU-MK/ml culture ⁺	
	7	42.6 \pm 7.6§
30	14	67.6 \pm 56.6
	21	17.0 \pm 11.8
	28	20.2 \pm 10.4

-18-

50 U/ml recombinant human IL-3 were added every 48 h; specific activity 10^8 CFUc/mg protein. 75 U/ml recombinant human IL-6 were added every 48 h; specific activity 10^7 CFU/mg protein.

*Cultures were demi-depopulated every 7 d.

- 5 +CFU-MK were assayed in serum-free fibrin clot culture containing 100 U/ml IL-3 colonies enumerated at days 18-24 of culture.

§Each point represents the mean \pm SD of triplicate assays.

Values are not corrected for the effects of demi-depopulated.

- 10 Table VI. Total CFU/GM and BFU-E Production by Sorted Cell Populations Stimulated with a Combination of IL-3 and IL-6

		Week					
Population		1	2	3	4	6	8
		CFU-GM (BFU-E)ml cultures					
15	CD34 ⁺ DR ⁻ CD15 ⁻	275(10)	286(4)	64	32	75	0
	CD34 ⁺ DR ⁻ CD15 ⁺	7(1)	26	0	0	0	0
	CD34 ⁺ DR ⁻ CD71 ⁻	220(5)	330(4)	132	18	43	0
	CD34 ⁺ DR ⁻ CD71 ⁺	13	16	0	0	0	0

Total CFU = CFU/ml culture/(1/2)ⁿ = number of previous

- 20 demi-depopulations. 50 U/ml recombinant human IL-3, specific activity 10^8 CFU/mg protein and 75 U/ml recombinant human IL-6, specific activity 10^7 CFU/mg protein were added every 48 h. Cells were seeded at 5×10^3 /ml.

-19-

Table VII. Differential Analysis of CD34⁺, DR⁻, CD15⁻
Cells after Addition of Various Cytokines

	Cytokines	Day	Blasts	Pro	Myelo	MM	Band %	Seg	Eo	Baso	E	Mo
5	Control	7	100									
	IL-1 α *	7	100									
		14	78									22
10	IL-6+	7	100									
		14	27	11		9		13		38		2
		21	9			48	2	7		17		17
		28				30		4				66
	GM-CSF ^S	7	25	24		27	3	21				
		14	9	1		46	3	21		13		7
15		21	3	2	1	62	3	5		22		2
		28	6		1	43	7	3		6	2	32
		35			4							96
		42			1							99
	IL-3 ^o	7	21	44		35				1		
		14	7	7		53				33		
20		21	8			44				48		
		28	5			35	3	9		35		13
		35	2			16	5	20		25		32
		42				15		2		20		63
	IL-1 α /IL-3	7	1	5	1	53	12	14		14		
		14	5			34	9			52		
25		21	1			53	4	3		31		8
		28	1			42	12	5		32		8
		35				20				27		53
		42				8				8		84
		56								11		89
	IL-6/IL-3	7	19	26	2	40	5	4		4		

SUBSTITUTE SHEET

-20-

Table VII (con't)

Cytokines	Day	Blasts	Pro	Myelo	MM	Band	Seg	Eo	Baso	E	Mo
	14	2	2		46	3	1		46		
	21	5	1		37	1	7		48		1
5	28	4	1		37	10	8		35		5
	42	1			8		1		9		81
	56				2				3		95

Differential cell counts were performed on Wright-Giemsa stained cytocentrifuge preparations of cells removed from liquid culture. 200 Cells per sample were classified; if 200 cells appeared on a slide, all were classified.

Abbreviations: Pro, promyelocytes; Myelo, myelocytes; MM, metamyelocytes; Band, neutrophil band form; Seg, segmented neutrophils; Eo, eosinophils; Baso, basophils; E, erythrocytes; and Mo, monocytes. *2.5 U/ml recombinant human IL-1a were added every 48 h; specific activity 10^8 CFU/mg protein. †50 U/ml recombinant human IL-3 were added every 48 h; specific activity 10^8 CFU/mg protein. §75 U/ml recombinant human IL-6 were added every 48 h; specific activity 10^7 CFU/mg protein. °12.5 U/ml recombinant human GM-CSF were added every 48 h; specific activity 5×10^7 CFU/mg protein.

-21-

Table VIII. Differential Analysis of CD34⁺, DR⁻, CD71⁻ Cells after Addition of Various Cytokines

	Cytokines	Day	Blasts	Pro	Myelo	MM	Band %	Seg	Eo	Baso	E	Mo
5	Control	7	90									10
		14	40									60
	IL-1 α *	7	82									18
	IL-6 ⁺	7	43	4								13
		14	33	20								47
10	GM-CSF [§]	7	39	33		9	5	6		5		2
		14	18	5		42	3	12		20		
		21	4		1	66	9	7				4
		28	2			61	3	1	8			24
		35	14			18	8	8	9			52
15		42										100
	IL-3 [°]	7	52	40		1	2	2		2	1	
		14	29	26		26	2	3		14		
		21	13	4	2	28	2	3		48		
		28	14	3		35	5	1		35		7
20		35	9			20	7	6		27		31
		42	2			5		4		16	2	71
	IL-1 α /IL-3	7	48	42			6	2	1		2	
		14	4	1	53	4	5		33			
		21	3			44	1	1		49		2
25		28	21	3		34	4	3	1	27		8
		35	3			23	4	29		20		21
		42	1			7	3	3		16		70
		56						1		8		91

Differential cell counts were performed on Wright-Giesma stained

-22-

cytocentrifuge preparations of cells removed from liquid culture.

200 cells per sample were classified; if < 200 cells appeared on a slide, all were classified. Abbreviations as in Table VII. *2.5 U/ml recombinant human IL-1a were added every 48 h; specific activity 10^8 CFU/mg protein. + 50 U/ml recombinant human IL-3 were added every 48 h; specific activity 10^8 CFU/mg protein. §75 U/ml recombinant human IL-6 were added every 48 h; specific activity 10^7 CFU/mg protein. °12.5 U/ml recombinant human GM-CSF were added every 48 h; specific activity 5×10^7 CFU/mg protein.

EXAMPLE 2

Long-term bone marrow cultures (LTBMC) were initiated with 5×10^3 CD34⁺DR⁻CD15⁻ marrow cells/ml in the absence of an adherent cell layer to which murine mast cell growth factor (MGF) alone or in combination with IL-3 or a GM-CSF/IL-3 fusion protein (FP; Williams et al. Exp. Hematol. 18: 615, 1990) were added every 48 hours. In cultures not receiving cytokines, viable cells were not detectable after two weeks while cultures receiving IL-3, FP, or MGF sustained hemopoiesis for 10 weeks. Addition of IL-3 or FP alone increased cell numbers by 10^3 fold by day 56, while the combination of MGF and FP expanded cell numbers 10^5 -fold (5×10^3 cells at day 0; 5.5×10^3 at day 56). Over the 10 week period of LTBMC, treatment with various cytokines led to the following cumulative increases over an input of 213 total assayable hematopoietic progenitor cells (HPC; CFU-GM+BFU-E+CFU-MK): IL-3, 868; FP, 1,265; MGF, 2,006 MGF+IL-3, 4,845; MGF+FP, 155,442. LTBMCs receiving MGF alone possessed a higher HPC cloning efficiency than those receiving IL-3 or FP and its addition increased the cloning efficiencies of cultures containing of IL-3 and FP. The presence of MGF did not increase the longevity of cultures receiving these cytokines.

SUBSTITUTE SHEET

-23-

Table IX

Total Cell Production of CD34⁺, DR⁻, CD15⁻ Cells after
Addition of Various Cytokines

		Day	
5	Cytokine	0	26
		Viable Cell count x 10 ³	
	None	5	0
	*IL-3	5	140 100%
	+GM-CSF	5	100
10	*FP	5	1,400
	MGF	5	520
	GM-CSF/IL-3	5	560
	MGF/GM-CSF	5	12,500 20%
	MGF/IL-3	5	1,200
15	MGF/FP	5	10,000

Total cells/ml culture/1/2Yn = number of previous cell
dilutions.

Cultures were periodically split to allow for cellular
expansion and to perform several analyses at different time
points.

*500pg/ml recombinant human IL-3 was added every 48 hours

+200.0 pg/ml recombinant human GM-CSF was added every 48 hours

*10.0 ng/ml of recombinant GM-CSF-IL-3 fusion protein was added
each day

25 100.0 ng/ml of murine recombinant stem cell factor (SCGF) was
added every 48 hours

-24-

Table X

Differential Analysis of CD34⁺, DR⁻, CD15⁻ Cells After
Addition of Various Cytokines on Day 26 of Suspension Culture

	Cytokines	Blasts	Pro	Myelo	MM	Band	Seg	Lymph	Eo	Baso	Mo	Norm
5	FP	3	7	9	9	27	3	5	2	9	0	5
	GM-CSF/IL-3	1	7	4	13	24	32	4	3	4	0	0
	MGF	32	4	9	9	13	12	7	1	1	12	0
	MGF/GM-CSF	21	10	15	12	14	7	5	2	3	11	0
	MGF/IL-3	38	3	15	12	13	4	2	2	4	7	2
10	MGF/FP	37	17	16	9	9	5	1	0	6	0	5

Differential cell counts were performed on Wright Giemsa stained cytocentrifuge preparations of cells removed from liquid culture.

200 cells per sample. Abbreviation used, Norm, normoblasts,
15 other abbreviations as in Table VII. Cytokines were added at same dose as detailed in legend of Table I.

Numerous modifications and variations of the present invention are possible in light of the above teachings; therefore, within the scope of the appended claims the
20 invention may be practiced otherwise than as particularly described.

Example 3

Liquid culture systems supplemented with repeated 48 hourly cytokine additions was utilized to study cell
25 populations cultured from two donors. Total cell production of CD34⁺DR⁻CD15⁻ cells is shown in Table XI while assayable CFU-GM in these cultures over time is recorded in Table XIII. In the absence of exogenous cytokines, total cell numbers declined over a 1 to 2-wk period and assayable
30 CFU-GM persisted for only a 1 to 2-wk period. In donor 1, MGF/FP cytokine combination promoted increased total cell production for 8 wk, by which time cell numbers represented over 110 x 10³ times the number present in the initial

-25-

seeding populations. In donor 2 the same cytokine combination promoted increased total cell production for 6 wk, by which time the cell numbers represented by over 16×10^3 times the number present in the initial seeding population. Assayable CFU-GM for donor 1 and donor 2 cultured with MGF/FP cytokine combination persisted for 6-8 wk and 3-4 wk, respectively and significantly surpassed the CFU-GM population initially assayable.

The cytokine combination MGF/IL-3 promoted over 2×10^3 fold increase in total cell production over the initial seeding for donor 1 at 6 wk and donor 2 at 8 wk. Additionally, viable cell counts remain high through 10 wk. The assayable expansion of CFU-GM for donor 1 and 2 cultured with MGF/IL-3 cytokine combination persisted for 6-8 wk for each donor and each significantly surpassed the CFU-GM population assayable initially.

Total BFU-E production by $CD34^+DR^-CD15^-$ cells is shown in Table XIV. In donor 1 and donor 2 the cytokine combination MGF/FP persisted for 1-2 wk and 3-4 wk, respectively with only donor 2 showing a significant increase over the BFU-E population initially assayable. The cytokine combination MGF/IL-3 persisted in Donor 1 for 2-3 wk and in donor 2 for 3-4 wk, with both showing significant increase in wk 1-2 over the BFU-E population initially assayable.

Total CFU-MK production by $CD34^+DR^-CD15^-$ cells is shown in Table XV. The cytokine combination of MGF/IL-3 for both donor 1 and 2 show CFU-MK persistence for through 10 wk and each has significantly surpassed the initially assayable CFU-MK population. Donors 1 and 2 show CFU-MK persistence for 6-8 wk and 8-10 wk, respectively, both showing significant increases over the initial CFU-MK population.

Morphological analysis of the cells in the suspension cultures of donor 1 during the period of observation revealed changes in the cellular composition of the population following the addition of various cytokines, see Table XII,

-26-

which shows the differential analysis of CD34⁺DR⁻CD15⁻ cells. Cultures receiving MGF/FP were composed of 11% blasts by 14 days and cultures receiving MGF/IL-3 were composed of 17% blasts by 14 days. The highest percentage of blasts by 14 days was in the cultures receiving MGF alone which were composed of 30% blasts. In contrast IL-3 and FP containing cultures had reduced the percentage of blasts cells appreciably by day 14.

Table XVI depicts the percentage of total cells which give rise to progenitor cells of colony forming units. Although MGF percentages are high the overall expansion of cultures receiving MGF is not as substantial, however the cultures receiving MGF/IL-3 cytokines provide high plating percentages and substantial overall expansion (see Tables XI-XV)

Table XI. Total Cell Production of CD34⁺, DR⁻, CD15⁻ Cells Cultured in the Absence of Various Cytokines

Viable cell count x 10 ³ /ml		Week						
20	Cytokine	1	2	3	4	6	8	10
		<u>Donor 1</u>						
	None	1	0	0	0	0	0	0
	IL-3 ¹	28	144	271	560	480	762	960
	GM-CSF ₂	12	107	436	1,085	2,680	2,080	1,760
25	IL-3/GM-CSF	23	244	742	1,620	1,979	2,035	2,720
	FP ³	42	262	587	1,240	3,000	1,494	480
	MGF ⁴	8	104	933	N.D. ⁵	1,680	1,760	640
	MGF/FP	101	1,211	35,100	101,000	262,400	550,000	100,000
	MGF/IL-3	38	213	978	2,820	10,800	3,680	5,120

-27-

<u>Donor 2</u>							
None	1	0	0	0	0	0	0
IL-3	24	180	650	605	1,400	960	864
FP	41	810	2,100	6,680	1,840	4,320	5,280
5 MGF	8	27	71	98	230	70	0
MGF/FP	100	1,280	15,700	6,400	81,000	19,520	0
MGF/IL-3	36	305	780	1,380	6,960	10,400	5,440

<u>Donor 3</u>					
MGF/FP	N.D.	5,040	14,400	14,800	8,960

- 10 Total cells = cells/ml culture / (n)ⁿ where n = number of
demi-depopulations.
Cultures were seeded at 5 x 10³ cells/ml.
¹500 pg/ml recombinant human IL-3 was added every 48 hours;
specific activity 3.5 x 10⁸ CFU/mg protein
- 15 ²250 pg/ml recombinant human GM-CSF was added every 48 hours;
specific activity 2 x 10⁸ CFU/mg protein.
- ³10 ng/ml recombinant human FP was added every 48 hours;
specific activity 1-2 x 10⁸ CFU/mg
- ⁴50 ng/ml recombinant murine MGF was added every 48 hours;
specific activity 10⁶ CFU/mg protein
- 20 ⁵ N.D. - not determined.

-28-

TABLE XII. Differential Analysis of CD34⁺ DR⁻ CD15⁻ Cells
following Culture with Various Cytokines

	Cytokines	Day	Blasts %	Pro	Myelo	Meta	Band	Seg	Baso	Eos	Mono
5	Post Sort IL-3 ¹	0	82	1	1				6		10
		7	10	8	16	2		9	50	2	3
		14	2	4	39	4	3	10	28		10
		28	3	6	13	3	1	6	61		7
		7	10	21	52	5		2	7		3
10	FP ²	14	1	4	17	8	3	20	14		33
		28		1	24	7	4	36	8		20
	MGF ³	7	54	39	3				1		3
		14	30	38	9	1	1		1		20
		28	1	7	21	18	13	15	1	1	23
15	MGF/FP	7	29	22	23	3		4	18		1
		14	11	22	16	4	2	4	13		28
		28	1	8	13	12	2	10	2		52
	MGF/IL-3	7	31	15	48			2	4		
		14	17	14	9	2	4	8	34		12
20		28		8	46	17	2	17	2		8

-29-

Differential cell counts were performed on Wright-Giemsa-stained cytocentrifuge preparations of cells removed from liquid culture. ² 100 cells per sample were classified. Abbreviations: Pro, promyelocyte; Myelo, myelocyte; Meta, metamyelocyte; Band, neutrophil band form; Seg, segmented neutrophil; Baso, basophil; Eos, eosinophil; Mono, monocyte.

- ¹ 500 pg/ml recombinant human IL-3, specific activity 3.5×10^2 CFU/ml protein
² 10 ng/ml recombinant human FP, specific activity $1-2 \times 10^3$ CFU/mg protein
³ 50 ng/ml recombinant murine MGF, specific activity 10^6 CFU/mg protein

Table XIII. Total CFU-GM Production by $CD34^+ DR^- CD15^-$ Cells Cultured in the Presence of Various Cytokines
 CFU-GM/ml culture¹

		Week					
Cytokine		1	2	3	4	6	8
		<u>Donor 1</u>					
20	None	8	0	0	0	0	0
	IL-3 ²	132	28	80	N.D. ⁵	N.D.	128
	GM-CSF ₃	192	112	88	N.D.	128	0
	IL-3/GM-CSF	196	104	36	N.D.	128	576
	FP ⁴	86	112	128	176	N.D.	64
25	MGF ⁵	290	396	608	448	96	0
	MGF/FP	376	1,600	14,800	38,000	80,000	0
	MGF/IL-3	144	348	104	416	2,528	192

-30-

<u>Donor 2</u>						
None	0	0	0	0	0	N.D.
IL-3	232	196	96	16	64	N.D.
FP	84	148	288	320	544	N.D.
5 MGF	106	152	360	64	128	N.D.
MGF/FP	114	1,440	10,600	N.D.	N.D.	N.D.
MGF/IL-3	62	240	504	32	1,024	N.D.

<u>Donor 3</u>						
MGF/FP	N.D.	12,448	32,264	32,264	1,254	0

10 Total CFU-GM = CFU-GM/ml culture/(n)ⁿ where n = number of previous demi-depopulations.

¹Cultures were seeded at 5×10^3 cells/ml. CFU-GM/ 5×10^3 cells in initial population: Donor 1, 150; Donor 2, 227, Donor 3, 144. Colonies grown in methylcellulose containing 500 pg/ml

15 GM-CSF and 1 U human urinary erythropoietin and enumerated after 14 days.

²500 pg/ml recombinant human IL-3 was added every 48 hours; specific activity 3.5×10^8 CFU/mg protein.

³250 pg/ml recombinant human GM-CSF was added every 48 hours; specific activity 2×10^8 CFU/mg protein.

⁴10 ng/ml recombinant human FP was added every 48 hours; specific activity $1-2 \times 10^3$ CFU/mg protein.

⁵ ng/ml recombinant murine MGF was added every 48 hours; specific activity 10^6 CFU/mg protein.

25 ⁶N.D. - not determined.

-31-

Table XIV. Total BFU-E Production by CD34⁺ DR⁻ CD15⁻ Cells Cultured in the Presence of Various Cytokines
BFU-E/ml culture¹

		Week			
5	Cytokine	1	2	3	4
			<u>Donor 1</u>		
	None	0	-	-	-
	IL-3	24	0	0	0
	GM-CSF	8	0	0	0
10	IL-3/GM-CSF	22	4	0	0
	FP	20	4	0	0
	MGF	8	40	0	0
	MGF/FP	98	0	0	0
	MGF/IL-3	238	4	0	0
15			<u>Donor 2</u>		
	C	0	-	-	-
	IL-3	40	28	0	0
	FP	132	68	56	16
	MGF	6	0	0	0
20	MGF/FP	662	100	200	0
	MGF/IL-3	1,062	272	40	0

Total BFU-E - BFU-E/ml culture/(N)ⁿ where n = number of previous demi-depopulations.

¹Cultures were seeded at 5×10^3 cells/ml. Each point
25 represents the mean of two separate experiments. Mean BFU-E/ 5×10^3 cells in initial population: = Donor 1, 173; Donor 2, 154. Colonies grown in methylcellulose containing 500 pg/ml GM-CSF and 1 U human urinary erythropoietin and enumerated at 12 days.

²500 pg/ml recombinant human IL-3 added every 48 hours;
30 specific activity 3.5×10^6 CFU/mg protein.

³250 pg/ml recombinant human GM-CSF added every 48 hours;

SUBSTITUTE SHEET

-32-

specific activity 2×10^8 CFU/mg protein.

⁴10 ng/ml recombinant human FP[added every 48 hours;

specific activity $1-2 \times 10^8$ CFU/mg protein.

⁵50 ng/ml recombinant murine MGF added every 48 hours;

5 specific activity 10^8 CFU/mg protein.

Table XV. Total CFU-MK Production by CD34⁺ DR⁻ CD15⁻
Cells Cultured in the Presence of Various Cytokines
CFU-MK/ml culture¹

10	Cytokine	Week					
		2	3	4	5	8	10
		<u>Donor 1</u>					
	None	0	0	0	0	0	0
	IL-3 ²	14	74	100	118	48	N.D. ⁶
	GM-CSF ₃	12	40	20	48	32	0
15	IL-3/GM-CSF	20	80	96	120	N.D.	N.D.
	FP ⁴	28	120	184	118	96	64
	MGF ⁵	6	12	36	20	0	0
	MGF/FP	40	120	120	120	N.D.	0
	MGF/IL-3	26	90	208	220	128	64
20		<u>Donor 2</u>					
	None	8	0	0	0	0	0
	IL-3	26	100	140	140	64	64
	GM-CSF	24	40	60	80	32	0
	IL-3/GM-CSF	40	120	160	200	64	64
25	FP	56	120	200	200	96	64
	MGF	10	3	60	60	0	0
	MGF/FP	56	200	200	200	40	0
	MGF/IL-3	34	120	240	260	160	192

Total CFU-MK = CFU-MK/ml culture/(N)ⁿ where n = number of
30 previous demi-depopulations.

¹Cultures were seeded at 5×10^3 cells/ml. Each point

-33-

represents the mean of two separate experiments. Mean CFU-MK/5 x 10³ cells in initial populations = 0. Colonies cultured in fibrin clot containing 1 ng IL-3 and enumerated at 15 days.

5 ²1 ng/ml recombinant human IL-3 was added every 48 hours; specific activity 3.5 x 10³ CFU/mg protein.

³200 pg/ml recombinant human GM-CSF was added every 48 hours; specific activity 2 x 10⁸ CFU/mg protein.

10 ⁴10 ng/ml recombinant human FP was added every 48 hours; specific activity 1-2 x 10⁸ CFU/mg protein.

⁵100 ng/ml recombinant murine MGF was added every 48 hours; specific activity 10⁶ CFU/mg protein.

⁶Not determined.

		Week					
15	Cytokine	1	2	3	4	6	8
		% plating Efficiency ¹					
	None	N.D. ⁶	-	-	-	-	-
	IL-3 ²	0.86	0.072	0.023	0.003	0.005	0.009
	GM-CSF ₃	1.67	0.105	0.020	N.D.	0.005	0.000
20	IL-3/GM-CSF	0.96	0.044	0.005	N.D.	0.006	0.028
	FP ⁴	0.42	0.039	0.019	0.010	0.015	0.002
	MGF ⁵	2.58	0.493	0.580	0.065	0.031	0.000
	MGF/FP	0.65	0.127	0.056	0.029	0.015	0.000
	MGF/IL-3	2.10	0.173	0.041	0.008	0.019	0.002

25 ¹% Plating Efficiency = colonies enumerated/cells cultured x 100%. Cells at each timepoint were counted and cultured in methylcellulose containing 500 pg GM-CSF and 1 U human urinary erythropoietin or in fibrin clot containing 1 ng IL-3 and

-34-

enumerated at 14 days. Each point represents the mean of two to four separate experiments. Mean cloning efficiency of initial (day 0) population: 4.54%

²500 pg/ml recombinant human IL-3 was added every 48 hours;
5 specific activity 3.5×10^8 CFU/mg protein

³200 pg/ml recombinant human GM-CSF was added every 48 hours; specific activity 2×10^8 CFU/mg protein.

⁴10 ng/ml recombinant human FP was added every 48 hours; specific activity $1-2 \times 10^8$ CFU/mg protein.

10 ⁵100 ng/ml recombinant murine MGF was added every 48 hours; specific activity 10^8 CFU/mg protein.

⁶N.D. - Not determined.

EXAMPLE 4

15 Serum-free long-term suspension human bone marrow culture system. Serum-free media was prepared as previously outlined by Ponting et al. (19). Both serum-free and serum-containing cultures were initiated with $CD34^+ DR^-$ $CD15^-$ cells and supplemented every 48 hours with KL and a GM-CSF/IL-3 fusion molecule (FP).

20 As can be seen in Table XVII, cultures maintained in serum-free media were characterized by far less total cell production than has been observed in comparable serum containing culture. Over the 6 weeks of observation, these LT BMCs exhibited a mere 24-fold increase in total cell
25 numbers, yet were characterized by a 6-fold increase in CFU-GM and a 1.8-fold increase in HPP-CFC. Remarkably, however, the progenitor cell cloning efficiency in serum-free cultures was 1.4% after 28 days of LT BMC (Table XVII) in

-35-

comparison to a cloning efficiency of 0.03% in comparable serum-containing cultures. These studies suggest that the serum-free culture system is preferred for expanding progenitor cell numbers at the expense of impairing the
 5 production of more differentiated cells.

TABLE XVII*

	Day in Culture	Cell No. x 10 ³	Progenitor Cells	
			CFU-GM	HPP-CFC
	0	10	375	40
10	14	30	744	9
	28	70	1,050	21
	42	140	140	42

* CD34⁺ DR⁻ CD15⁻ cells were suspended in serum-free medium and supplemented with 100 ng/ml of KL and 10 ng/ml of
 15 FP every 48 hours.

-36-

References:

1. Gordon, M.Y., C.R. Dowding, G.P. Riley, and M.F. Greaves. 1987. Characterization of stroma-dependent blast colony-forming cells in human marrow. J. Cell. Physiol 5 120:150-156.
2. Brandt, J.E., N. Baird, L. Lu, E. Srour, and R. Hoffman. 1988. Characterization of a human hematopoietic progenitor cell capable of forming blast cell containing colonies in vitro. J. Clin. Invest. 82:1017-1027.
- 10 3. Dexter, T.M., T.D. Allen, and L.G. Lajtha. 1977. Conditions controlling the proliferation of hematopoietic stem cells in vitro. J. Cell. Physiol. 91:335--344.
4. Roberts, R.A., E. Spooncer, E.K. Parkinson, B.I. Lord, T.D. Allen, and T.M. Dexter. 1987. Metabolically 15 inactive 3T3 cells can substitute for marrow stromal cells to promote the proliferation and development of multipotent hematopoietic stem cells. J. Cell. Physiol. 132:203-214.
5. Eliason, J.F., B. Thorens, V. Kindler, and P. Vassalli. 1988. The roles of granulocyte-macrophage 20 colony-stimulating factor and interleukin-3 in stromal cell-mediated hemopoiesis in vivo. Exp. Hematol. 16:307-312.
6. Strauss, L.C., R.K. Stuart, and C.I. Civin. 1983. Antigenic analysis of hematopoiesis. I. Expression of the My-1 granulocyte surface antigen on human marrow cells and 25 leukemic cell lines. Blood. 61:1222-1231.
7. Sieff, C., D. Bicknell, G. Caine, J. Robinson, G. Lam, and M.F. Greaves. 1982. Changes in cell surface antigen expression during hemopoietic differentiation. Blood. 60:703-713.
- 30 8. McNiece, I.K., F.M. Stewart, D.M. Deacon, D.S. Temeles, K.M. Zsebo, S.C. Clark, and P.J. Quesenberry. 1989. Detection of a human CFC with a high proliferative potential. Blood. 74:609-612.

SUBSTITUTE SHEET

-37-

9. Brno, E., R. Briddell, and R. Hoffman. 1988. Effect of recombinant and purified hematopoietic growth factors on human megakaryocyte colony formation. *Exp. Hematol.* 16:371-377.
- 5 10. Moore, M.A.S., and A.P.C. Sheridan. 1979. Pluripotent stem cell replication in continuous human, prosimian, and murine bone marrow culture. *Blood Cells.* 5:297-311.
11. Hocking, W.G., and D.W. Golde. 1980. Long-term
10 human bone marrow cultures. *Blood* 56:118-124.
12. Gartner, S., and H.S. Kaplan. 1980. Long-term culture of human bone marrow cells. *Proc. Natl. Acad. Sci. USA*, 77:4756-4759.
13. Slovic, F.T., C.N. Abboud, .K. Brennan, and M.A.
15 Lichtman. 1984. Survival of granulocytic progenitors in the anonadherent and adherent compartments of human long-term marrow cultures. *Exp. Hematol.* 12:327-338.
14. Coulombel, L., A.C. Eaves, and C.J. Eaves. 1983. Enzymatic treatment of long-term human marrow cultures
20 reveals the preferential location of primitive hematopoietic progenitor in the adherent layer. *Blood* 62:291-297.
15. Gordon, M.Y., J.A. Hibben, S. Dowding, E.C. Gordon-Smith, and J.M. Goldman. 1985. Separation of human blast progenitors from granulocytic, erythroid
25 megakaryocytic, and mixed colony forming cells by "panning" on cultures marrow-derived stromal layers. *Exp. Hematol.* 13:937-940.
16. Li, D.L., and G.R. Johnson. 1985. Stimulation of multipotential, erythroid and other murine hematopoietic
30 progenitor cells by adherent cell lines in the absence of detectable multi-CSF (IL-3). *Nature (Lond.)*. 316:633-636.
17. Tsai, S., C.A. Sieff, and D.G. Nathan. 1986. Stromal cell-associated erythropoiesis. *Blood*. 67:1418-1426.
18. McNiece, I.K., Langley, K.E., and Zsebo, K.M.,
35 1991. Recombinant Human Stem Cell Factor Synergises with

-38-

GM-CSF, G-CSF, IL-3 and Epo to Stimulate Human Progenitor Cells of the Myeloid and Erythroid Lineages, Exp. Hematol., 19:226, 231.

19. Ponting, I.K.D.; Heyworth, C.M.; Cormier, F. and
5 Dexter, T.M., Growth Factors, 4:165-173, 1991.

-39-

WHAT IS CLAIMED IS:

1. A process for supporting mammalian bone marrow cells in a culture medium, which comprises:
maintaining bone marrow cells in a culture medium
5 which is essentially free of stromal cells said culture medium containing at least one cytokine effective for supporting said cells.
2. A process as in Claim 1, wherein said bone marrow cells are hematopoietic stem cells.
- 10 3. A process as in Claim 1, wherein said bone marrow cells are hematopoietic progenitor cells.
4. A process as in Claim 1, wherein said bone marrow cells are $CD34^{+} DR^{-} CD15^{-}$ cells.
5. A process as in Claim 1, wherein at least one said
15 cytokine is selected from the group consisting of IL-1; IL-3; IL-6; MGF; Fusion Protein of GM-CSF/IL-3.
6. A process for supporting mammalian bone marrow cells in a culture medium, which comprises:
maintaining bone marrow cells in a culture medium
20 which contains a combination of cytokines effective for supporting said cells.
7. A process as in Claim 6, wherein said culture medium is essentially free of stromal cells.
8. A process as in Claim 6, wherein said bone marrow
25 cells are hematopoietic stem cells.
9. A process as in Claim 6, wherein said bone marrow cells are hematopoietic progenitor cells.

SUBSTITUTE SHEET

-40-

10. A process as in Claim 6, wherein said bone marrow cells are CD34⁺ DR⁻ CD15⁻.

11. A process of Claim 7 wherein said culture medium contains at least one of the following cytokine combinations: IL-1 and IL-3; IL-3 and IL-6; IL-3 and MGF; IL-3 and GM-CSF; and MGF and Fusion Protein of GM-CSF/IL-3.

12. A cell population of CD34⁺ DR⁻ CD15⁻ supported in accordance with the process as in Claim 6, wherein said population has doubled in a time period not to exceed 15 days.

10 13. A cell population as in Claim 12, wherein said population has doubled in a time period of at least 7 and not exceeding 15 days.

14. A cell population of bone marrow cells supported in accordance with the process as in Claim 6 wherein said
15 population has doubled in a time period not to exceed 15 days.

15. A cell population as in Claim 14, wherein said population having doubled in a time period of at least 7 and not exceeding 15 days.

16. A cell population of hematopoietic stem cells
20 supported in accordance with the process as in Claim 6, wherein said population has doubled in a time period not to exceed 15 days.

17. A cell population as in Claim 16, wherein said population has doubled in a time period of at least 7 and not
25 exceeding 15 days.

-41-

18. A cell population of hematopoietic progenitor cells supported in accordance with the process as in Claim 6 wherein said population has doubled in a time period not to exceed 15 days.

5 19. A cell population as in Claim 18, wherein said population has doubled in a time period of at least 7 and not exceeding 15 days.

20. A composition comprising:
an expanded mammalian bone marrow cell culture which
10 is essentially free of stromal cells, said culture containing at least one cytokine,
said culture having a cell population which has doubled in a time period not to exceed 15 days.

21. A composition as in Claim 20, wherein said cell
15 population has doubled in a time period of at least 7 and not exceeding 15 days.

22. A composition as in Claim 20, wherein at least one said cytokine is selected from the group consisting of IL-1; IL-3; IL-6; MGF; Fusion protein of GM-CSF/IL-3 and GM-CSF.

20 23. A composition comprising:
an expended mammalian bone marrow cell culture containing a combination of cytokines, said culture having a cell population which has doubled in a time period not to exceed 15 days.

25 24. A composition of Claim 22, wherein said cell population has doubled in a time period of at least 7 and not exceeding 15 days.

SUBSTITUTE SHEET

-42-

25. A composition of Claim 23, wherein said culture is essentially free of stromal cells.

26. A composition of Claim 23, wherein said culture contains at least one of the following cytokine combinations
5 IL-1/IL-3; IL-3/IL-6; IL-3/MGF; IL-3/GM-CSF; and MGF/Fusion Protein of GM-CSF/IL-3.

27. A process as in Claim 1, wherein the culture medium is essentially serum-free.

28. A process as in Claim 1, wherein the culture medium
10 contains MGF.

29. A process as in Claim 11, wherein the culture medium is essentially serum-free.

30. A process as in Claim 28, wherein the culture medium is essentially serum-free.

15 31. A process as in Claim 28, wherein the culture medium contains a combination of MGF with another cytokine.

32. A process as in Claim 30, wherein the culture medium contains a combination of MGF with another cytokine.

20 33. A cell population of bone marrow cells supported in accordance with the process as in Claim 27, wherein said population has doubled in a time period not exceeding 15 days.

25 34. A cell population of hematopoietic stem cells supported in accordance with the process as in Claim 27, wherein said population has doubled in a time period not exceeding 15 days.

-43-

35. A cell population of hematopoietic progenitor cells supported in accordance with the process as in Claim 27, wherein said population has doubled in a time period not exceeding 15 days.

5 36. A cell population of bone marrow cells supported in accordance with the process as in Claim 28, wherein said population has doubled in a time period not exceeding 15 days.

10 37. A cell population of hematopoietic stem cells supported in accordance with the process as in Claim 28, wherein said population has doubled in a time period not exceeding 15 days.

15 38. A cell population of hematopoietic progenitor cells supported in accordance with the process as in Claim 28, wherein said population has doubled in a time period not exceeding 15 days.

39. A composition as in Claim 20, wherein the culture contains MGF.

40. A composition as in Claim 20, wherein the culture is essentially serum-free.

20 41. A composition as in Claim 23, wherein the culture contains MGF.

42. A composition as in Claim 23, wherein the culture is essentially serum-free.

AMENDED CLAIMS

[received by the International Bureau
on 02 September 1992 (02.09.92);
original claims 1-42 replaced by amended claims 1-25
(4 pages)]

1. A process for supporting mammalian bone marrow cells in a culture medium, which comprises:
maintaining bone marrow cells in a culture medium
5 which is essentially free from stromal cells and essentially serum-free, said culture medium containing MGF at least one other cytokine which in combination are effective for supporting said cells.
2. A process as in Claim 1, wherein said bone marrow
10 cells are hematopoietic stem cells.
3. A process as in Claim 1, wherein said bone marrow cells are hematopoietic progenitor cells.
4. A process as in Claim 1, wherein said bone marrow cells are $CD34^{+} DR^{-} CD15^{-}$ cells.
- 15 5. A process as in Claim 1, wherein said at least one other cytokine is selected from the group consisting of IL-1; IL-3; IL-6; Fusion Protein of GM-CSF/IL-3.
6. A process for supporting mammalian bone marrow cells in a culture medium, which comprises:
20 maintaining bone marrow cells in an essentially serum-free culture medium which contains a combination of cytokines including MGF and effective for supporting said cells.

7. A process as in Claim 6, wherein said culture medium is essentially free of stromal cells.

8. A process as in Claim 6, wherein said bone marrow cells are hematopoietic stem cells.

5 9. A process as in Claim 6, wherein said bone marrow cells are hematopoietic progenitor cells.

10. A process as in Claim 6, wherein said bone marrow cells are $CD34^{+} DR^{-} CD15^{-}$.

11. A cell population of $CD34^{+} DR^{-} CD15^{-}$
10 supported in accordance with the process as in Claim 6, wherein said population has doubled in a time period not to exceed 15 days.

12. A cell population as in Claim 11, wherein said population has doubled in a time period of at least 7 and not
15 exceeding 15 days.

13. A cell population of bone marrow cells supported in accordance with the process as in Claim 6, wherein said population has doubled in a time period not to exceed 15 days.

14. A cell population as in Claim 13, wherein said
20 population having doubled in a time period of at least 7 and not exceeding 15 days.

15. A cell population of hematopoietic stem cells supported in accordance with the process as in Claim 6, wherein said population has doubled in a time period not to exceed 15 days.

5 16. A cell population as in Claim 15, wherein said population has doubled in a time period to at least 7 and not exceeding 15 days.

10 17. A cell population of hematopoietic progenitor cells supported in accordance with the process as in Claim 6, wherein said population has doubled in a time period not to exceed 15 days.

18. A cell population as in Claim 17, wherein said population has doubled in a time period to at least 7 and not exceeding 15 days.

15 19. A composition comprising:
an expanded mammalian bone marrow cell culture which is essentially free of stromal cells and essentially serum-free, said culture containing MGF and at least one other cytokine,
20 said culture having a cell population which has doubled in a time period not to exceed 15 days.

20. A composition as in Claim 19, wherein said cell population has doubled in a time period of at least 7 and not exceeding 15 days.

21. A composition as in Claim 19, wherein said at least one other cytokine is selected from the group consisting of IL-1; IL-3; IL-6; Fusion Protein of GM-CSF/IL-3 and GM-CSF.

22. A composition comprising:
5 an expanded mammalian bone marrow cell culture containing a combination of cytokines including MGF, said culture being essentially serum-free and having a cell population which has doubled in a time period not to exceed 15 days.


10 23. A composition of Claim 22, wherein said cell population has doubled in a time period of at least 7 and not exceeding 15 days.

24. A composition of Claim 23, wherein said culture is essentially free of stromal cells.

15 25. A composition of Claim 23, wherein said culture contains at least one of the following cytokine combination: IL-3/MGF; and MGF/Fusion Protein of GM-CSF/IL-3.

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US92/02895

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ³		
According to International Patent Classification (IPC) or to both National Classification and IPC IPC (5) : C12N 5/00 US CL : 435/240.1		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁴		
Classification System	Classification Symbols	
U.S.	435/240.1	
Documentation Searched other than Minimum Documentation to the extent that such Documents are included in the Fields Searched ⁵		
APS, Dialog		
III. DOCUMENTS CONSIDERED TO BE RELEVANT ¹⁴		
Category ¹⁶	Citation of Document, ¹⁶ with indication, where appropriate, of the relevant passages ¹⁷	Relevant to Claim No. ¹⁸
X	J. Clin. Invest., Vol. 86, issued September 1990, J. Brandt et al., "Cytokine-dependent long-term culture of highly enriched precursors of hematopoietic progenitor cells from human bone marrow", pages 932-941, see entire document.	1-38
X/Y	Exp. Hematol., Vol. 18, Issued 1990, D.E. Williams et al., "Enhanced biological activity of a human GM-CSF/IL-3 fusion protein", page 615, see entire document.	1-38/1-38
Y	Blood, Vol. 64, No. 2, issued August 1984, R. J. Gualtieri et al., "Hematopoietic regulatory factors produced in long-term murine bone marrow cultures and the effect of in vitro irradiation", pages 516-525, see entire document.	1-38
Y	Blood, Vol. 73, No. 7, issued 15 May 1989, M. Kobayashi et al., "Interleukin-3 is significantly more effective than other colony-stimulating factors in long-term maintenance of human bone marrow-derived colony-forming cells in vitro", pages 1836-1841, see entire document.	1-38
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>¹⁵ Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"&" document member of the same patent family</p> </div> </div>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search ²	Date of Mailing of this International Search Report ²	
15 June 1992	01 JUL 1992	
International Searching Authority ¹	Signature of Authorized Officer ²⁰	
ISA/US	<div style="text-align: center;">  KAREN COCHRANE CARLSON, PH.D. </div>	

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

X,P	Blood Cells, Vol. 17, No. 2, issued 29 April 1991, E. F. Srour et al., "Human CD34+HLA-DR- bone marrow cells contain progenitor cells capable of self-renewal, multilineage differentiation, and long-term in vitro hematopoiesis", pages 287-295, see entire document.	1-26, 29
X,P	J. Immunol., Vol. 148, No. 3, issued 01 February 1992, E. F. Srour et al., "Relationship between cytokine-dependent cell cycle progression and MHC class II antigen expression by human CD34+ HLA-DR- bone marrow cells", pages 815-820, see entire document.	1-26, 29

V. ☐ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE¹

1. ☐ Claim numbers , because they relate to subject matter (1) not required to be searched by this Authority, namely:
2. ☐ Claim numbers , because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out (1), specifically:
3. ☐ Claim numbers , because they are dependent claims not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. ☐ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING²

This International Searching Authority found multiple inventions in this international application as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.
2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:
3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:
4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Search Authority did not invite payment of any additional fee.

Remark on protest

- ☐ The additional search fees were accompanied by applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category*	Citation of Document, ¹⁶ with indication, where appropriate, of the relevant passages ¹⁷	Relevant to Claim No. ¹⁸
X,P	Blood, Vol. 79, No. 3, issued 01 February 1992, J. Brandt et al., "Role of <u>c-kit</u> ligand in the expansion of human hematopoietic progenitor cells", pages 634-641, see entire document.	1-38.